Prospective cohort study investigates METTL3's impact on clinical outcomes in metastatic colorectal cancer, suggesting its potential as a biomarker.
Key Points
This study aims to explore METTL3 expression in metastatic colorectal cancer (mCRC) and its impact on clinical features and treatment response.
Enrolled sixty patients with metastatic colorectal cancer at South Egypt Cancer Institute.
Evaluated METTL3 expression using immunohistochemistry.
Analyzed METTL3 association with clinicopathological features and treatment outcomes.
Elevated METTL3 expression correlated with increased synchronous metastasis and higher metastatic site count.
Higher METTL3 was linked to greater lymphovascular invasion, perineural invasion, and a non-brisk immune response.
METTL3 overexpression was associated with lower response rates to oxaliplatin-based therapy and shorter progression-free survival and overall survival (p < 0.05).